<PAGE>
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
_________________________________________
SCHEDULE 13D
(Rule 13d-101)
INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(a) AND
AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a)
(Amendment No. 4)
BioSource International, Inc.
__________________
(Name of Issuer)
Common Stock, par value $0.001 per share
___________________________
(Title of Class of Securities)
09066H104
---------
(CUSIP Number)
Genstar Capital LLC
555 California Street, Suite 4850
San Francisco, California 94104
(415) 834-2350
______________________________________________
(Name, Address and Telephone Number of Person
Authorized to Receive Notices and Communications)
Copy to:
Scott R. Haber
Latham & Watkins
505 Montgomery Street, Suite 1900
San Francisco, California 94111-2562
(415) 391-0600
September 15, 2000
__________________________________________________
(Date of Event Which Requires Filing of This Statement)
If the filing person has previously filed a statement on Schedule 13G to
report the acquisition which is the subject of this Schedule 13D, and is filing
this statement because of Rule 13d-1(e), 13d-1(f) or 13d-1(g), check the
following box [ ].
(Continued on following pages)
<PAGE>
SCHEDULE 13D
-------------------------- --------------------------
CUSIP No. 09066H104 Page 2 of 12 Pages
-------------------------- --------------------------
------------------------------------------------------------------------------
1. Names of Reporting Person
Genstar Capital LLC
------------------------------------------------------------------------------
2. Check the Appropriate Box if a Member of a Group (a) [_]
(b) [X]
------------------------------------------------------------------------------
3. SEC Use Only
------------------------------------------------------------------------------
4. Source of Funds
AF, OO
------------------------------------------------------------------------------
5. Check Box if Disclosure of Legal Proceedings is Required Pursuant
to Items 2(d) or 2(e) [_]
------------------------------------------------------------------------------
6. Citizenship or Place of Organization
Delaware
------------------------------------------------------------------------------
Sole Voting Power
7.
Number of
-0- shares of Common Stock
Shares -----------------------------------------------------------
Shared Voting Power
Beneficially 8.
-2,967,220- shares of Common Stock (includes
Owned By 1,262,542 shares of Common Stock issuable upon
exercise of Warrants)
-----------------------------------------------------------
Each Sole Dispositive Power
9
Reporting -0- shares of Common Stock
Person -----------------------------------------------------------
Shared Dispositive Power
With 10
-2,967,220- shares of Common Stock (includes
1,262,542 shares of Common Stock issuable upon
exercise of Warrants)
------------------------------------------------------------------------------
11. Aggregate Amount Beneficially Owned by Each Reporting Person
-2,967,220- shares of Common Stock (includes 1,262,542 shares of Common
Stock issuable upon exercise of Warrants)
------------------------------------------------------------------------------
12. Check Box if the Aggregate Amount in Row (11) Excludes Certain Shares
[_]
------------------------------------------------------------------------------
13. Percent of Class Represented by Amount in Row (11)
26.6%
------------------------------------------------------------------------------
Type of Reporting Person
14
OO
------------------------------------------------------------------------------
2
<PAGE>
SCHEDULE 13D
-------------------------- --------------------------
CUSIP No. 09066H104 Page 3 of 12 Pages
-------------------------- --------------------------
------------------------------------------------------------------------------
1. Names of Reporting Person
Genstar Capital Partners II, L.P.
------------------------------------------------------------------------------
2. Check the Appropriate Box if a Member of a Group (a) [_]
(b) [X]
------------------------------------------------------------------------------
3. SEC Use Only
------------------------------------------------------------------------------
4. Source of Funds
AF, OO
------------------------------------------------------------------------------
5. Check Box if Disclosure of Legal Proceedings is Required Pursuant
to Items 2(d) or 2(e) [_]
------------------------------------------------------------------------------
6. Citizenship or Place of Organization
Delaware
------------------------------------------------------------------------------
Sole Voting Power
7.
Number of
-0- shares of Common Stock
Shares -----------------------------------------------------------
Shared Voting Power
Beneficially 8.
-2,967,220- shares of Common Stock (includes
Owned By 1,262,542 shares of Common Stock issuable upon
exercise of Warrants)
-----------------------------------------------------------
Each Sole Dispositive Power
9
Reporting -0- shares of Common Stock
Person -----------------------------------------------------------
Shared Dispositive Power
With 10
-2,967,220- shares of Common Stock (includes
1,262,542 shares of Common Stock issuable upon
exercise of Warrants)
------------------------------------------------------------------------------
11. Aggregate Amount Beneficially Owned by Each Reporting Person
-2,967,220- shares of Common Stock (includes 1,262,542 shares of Common
Stock issuable upon exercise of Warrants)
------------------------------------------------------------------------------
12. Check Box if the Aggregate Amount in Row (11) Excludes Certain Shares
[_]
------------------------------------------------------------------------------
13. Percent of Class Represented by Amount in Row (11)
26.6%
------------------------------------------------------------------------------
Type of Reporting Person
14
PN
------------------------------------------------------------------------------
3
<PAGE>
SCHEDULE 13D
-------------------------- --------------------------
CUSIP No. 09066H104 Page 4 of 12 Pages
-------------------------- --------------------------
------------------------------------------------------------------------------
1. Names of Reporting Person
Stargen II LLC
------------------------------------------------------------------------------
2. Check the Appropriate Box if a Member of a Group (a) [_]
(b) [X]
------------------------------------------------------------------------------
3. SEC Use Only
------------------------------------------------------------------------------
4. Source of Funds
AF, OO
------------------------------------------------------------------------------
5. Check Box if Disclosure of Legal Proceedings is Required Pursuant
to Items 2(d) Or 2(e) [_]
------------------------------------------------------------------------------
6. Citizenship or Place of Organization
Delaware
------------------------------------------------------------------------------
Sole Voting Power
7.
Number of
-0- shares of Common Stock
Shares -----------------------------------------------------------
Shared Voting Power
Beneficially 8.
-57,480- shares of Common Stock (includes 24,458
Owned By shares of Common Stock issuable upon exercise of
Warrants)
Each
-----------------------------------------------------------
Reporting Sole Dispositive Power
9
Person -0- shares of Common Stock
With -----------------------------------------------------------
Shared Dispositive Power
10
-57,480- shares of Common Stock (includes 24,458
shares of Common Stock issuable upon exercise of
Warrants)
------------------------------------------------------------------------------
11. Aggregate Amount Beneficially Owned by Each Reporting Person
-57,480- shares of Common Stock (includes 24,458 shares of Common Stock
issuable upon exercise of Warrants)
------------------------------------------------------------------------------
12. Check Box if the Aggregate Amount in Row (11) Excludes Certain Shares
[_]
------------------------------------------------------------------------------
13. Percent of Class Represented by Amount in Row (11)
0.6%
------------------------------------------------------------------------------
Type of Reporting Person
14
OO
------------------------------------------------------------------------------
4
<PAGE>
SCHEDULE 13D
-------------------------- --------------------------
CUSIP No. 09066H104 Page 5 of 12 Pages
-------------------------- --------------------------
------------------------------------------------------------------------------
1. Names of Reporting Person
Jean-Pierre L. Conte
------------------------------------------------------------------------------
2. Check the Appropriate Box if a Member of a Group (a) [_]
(b) [X]
------------------------------------------------------------------------------
3. SEC Use Only
------------------------------------------------------------------------------
4. Source of Funds
PF, AF
------------------------------------------------------------------------------
5. Check Box if Disclosure of Legal Proceedings is Required Pursuant
to Items 2(d) Or 2(e) [_]
------------------------------------------------------------------------------
6. Citizenship or Place of Organization
United States of America
------------------------------------------------------------------------------
Sole Voting Power
7.
Number of
-0- shares of Common Stock
Shares -----------------------------------------------------------
Shared Voting Power
Beneficially 8.
-3,024,700- shares of Common Stock (includes
Owned By 1,287,000 shares of Common Stock issuable upon
exercise of Warrants)
-----------------------------------------------------------
Each Sole Dispositive Power
9
Reporting -0- shares of Common Stock
Person -----------------------------------------------------------
Shared Dispositive Power
With 10
-3,024,700- shares of Common Stock (includes 1,287,000
shares of Common Stock issuable upon exercise of
Warrants)
------------------------------------------------------------------------------
11. Aggregate Amount Beneficially Owned by Each Reporting Person
-3,024,700- shares of Common Stock (includes 1,287,000 shares of Common
Stock issuable upon exercise of Warrants)
------------------------------------------------------------------------------
12. Check Box if the Aggregate Amount in Row (11) Excludes Certain Shares
[_]
------------------------------------------------------------------------------
13. Percent of Class Represented by Amount in Row (11)
27.0%
------------------------------------------------------------------------------
Type of Reporting Person
14
IN
------------------------------------------------------------------------------
5
<PAGE>
SCHEDULE 13D
-------------------------- --------------------------
CUSIP No. 09066H104 Page 6 of 12 Pages
-------------------------- --------------------------
------------------------------------------------------------------------------
1. Names of Reporting Person
Richard F. Hoskins
------------------------------------------------------------------------------
2. Check the Appropriate Box if a Member of a Group (a) [_]
(b) [X]
------------------------------------------------------------------------------
3. SEC Use Only
------------------------------------------------------------------------------
4. Source of Funds
PF, AF
------------------------------------------------------------------------------
5. Check Box if Disclosure of Legal Proceedings is Required Pursuant
to Items 2(d) or 2(e) [_]
------------------------------------------------------------------------------
6. Citizenship or Place of Organization
United States of America
------------------------------------------------------------------------------
Sole Voting Power
7.
Number of
-0- shares of Common Stock
Shares -----------------------------------------------------------
Shared Voting Power
Beneficially 8.
-3,024,700- shares of Common Stock (includes
Owned By 1,287,000 shares of Common Stock issuable upon
exercise of Warrants)
-----------------------------------------------------------
Each Sole Dispositive Power
9
Reporting -0- shares of Common Stock
Person -----------------------------------------------------------
Shared Dispositive Power
With 10
-3,024,700- shares of Common Stock (includes
1,287,000 shares of Common Stock issuable upon
exercise of Warrants)
------------------------------------------------------------------------------
11. Aggregate Amount Beneficially Owned by Each Reporting Person
-3,024,700- shares of Common Stock (includes 1,287,000 shares of Common
Stock issuable upon exercise of Warrants)
------------------------------------------------------------------------------
12. Check Box if the Aggregate Amount in Row (11) Excludes Certain Shares
[_]
------------------------------------------------------------------------------
13. Percent of Class Represented by Amount in Row (11)
27.0%
------------------------------------------------------------------------------
Type of Reporting Person
14
IN
------------------------------------------------------------------------------
6
<PAGE>
SCHEDULE 13D
-------------------------- --------------------------
CUSIP No. 09066H104 Page 7 of 12 Pages
-------------------------- --------------------------
------------------------------------------------------------------------------
1. Names of Reporting Person
Richard D. Paterson
------------------------------------------------------------------------------
2. Check the Appropriate Box if a Member of a Group (a) [_]
(b) [X]
------------------------------------------------------------------------------
3. SEC Use Only
------------------------------------------------------------------------------
4. Source of Funds
PF, AF
------------------------------------------------------------------------------
5. Check Box if Disclosure of Legal Proceedings is Required Pursuant
to Items 2(d) or 2(e) [_]
------------------------------------------------------------------------------
6. Citizenship or Place of Organization
Canada
------------------------------------------------------------------------------
Sole Voting Power
7.
Number of
-0- shares of Common Stock
Shares -----------------------------------------------------------
Shared Voting Power
Beneficially 8.
-3,024,700- shares of Common Stock (includes
Owned By 1,287,000 shares of Common Stock issuable upon
exercise of Warrants)
-----------------------------------------------------------
Each Sole Dispositive Power
9
Reporting -0- shares of Common Stock
Person -----------------------------------------------------------
Shared Dispositive Power
With 10
-3,024,700- shares of Common Stock (includes
1,287,000 shares of Common Stock issuable upon
exercise of Warrants)
------------------------------------------------------------------------------
11. Aggregate Amount Beneficially Owned by Each Reporting Person
-3,024,700- shares of Common Stock (includes 1,287,000 shares of Common
Stock issuable upon exercise of Warrants)
------------------------------------------------------------------------------
12. Check Box if the Aggregate Amount in Row (11) Excludes Certain Shares
[_]
------------------------------------------------------------------------------
13. Percent of Class Represented by Amount in Row (11)
27.0%
------------------------------------------------------------------------------
Type of Reporting Person
14
IN
------------------------------------------------------------------------------
7
<PAGE>
SCHEDULE 13D
-------------------------- --------------------------
CUSIP No. 09066H104 Page 8 of 12 Pages
-------------------------- --------------------------
------------------------------------------------------------------------------
1. Name of Reporting Person
Robert J. Weltman
------------------------------------------------------------------------------
2. Check the Appropriate Box if a Member of a Group (a) [_]
(b) [X]
------------------------------------------------------------------------------
3. SEC Use Only
------------------------------------------------------------------------------
4. Source of Funds
PF, AF
------------------------------------------------------------------------------
5. Check Box if Disclosure of Legal Proceedings is Required Pursuant
to Items 2(d) or 2(e) [_]
------------------------------------------------------------------------------
6. Citizenship or Place of Organization
United States of America
------------------------------------------------------------------------------
Sole Voting Power
7.
Number of
-0- shares of Common Stock
Shares -----------------------------------------------------------
Shared Voting Power
Beneficially 8.
Owned By -0- shares of Common Stock
-----------------------------------------------------------
Each Sole Dispositive Power
9
Reporting -0- shares of Common Stock
Person -----------------------------------------------------------
Shared Dispositive Power
With 10
-0- shares of Common Stock
------------------------------------------------------------------------------
11. Aggregate Amount Beneficially Owned by Each Reporting Person
-0- shares of Common Stock
------------------------------------------------------------------------------
12. Check Box if the Aggregate Amount in Row (11) Excludes Certain Shares
[_]
------------------------------------------------------------------------------
13. Percent of Class Represented by Amount in Row (11)
0.0%
------------------------------------------------------------------------------
Type of Reporting Person
14.
IN
------------------------------------------------------------------------------
8
<PAGE>
This Amendment No. 4 to Schedule 13D ("Amendment No. 4") amends the
Schedule 13D filed with the Securities and Exchange Commission (the
"Commission") on January 20, 2000, as amended (collectively, the "Schedule 13D")
by the undersigned Reporting Persons relating to shares of common stock, par
value $0.001 per share (the "Common Stock"), of BioSource International, Inc., a
Delaware corporation ("BioSource" or the "Company"). Unless otherwise
indicated, all capitalized terms used herein but not defined herein shall have
the same meanings as set forth in the Schedule 13D.
Item 2. Identity and Background.
-----------------------
Item 2 to the Schedule 13D is hereby amended to add the following
information:
(a)-(c), (f). This statement is being filed by the Reporting Persons
and Robert J. Weltman ("Mr. Weltman"). The agreement among the Reporting
Persons and Mr. Weltman relating to the joint filing of this statement is
attached as Exhibit 1 hereto.
Mr. Weltman is a Vice President and a member (but not a managing
member) of Genstar Capital and a member (but not a managing member) of Stargen,
and his present principal occupation or employment is as a Vice President of
Genstar Capital. Mr. Weltman's business address is 555 California Street, Suite
4850, San Francisco, California 94104. Mr. Weltman is a United States citizen.
(d), (e). During the last five years, Mr. Weltman has not (1) been
convicted in a criminal proceeding (excluding traffic violations or similar
misdemeanors) or (2) been a party to a civil proceeding of a judicial or
administrative body of competent jurisdiction and as a result of such proceeding
was or is subject to a judgment, decree or final order enjoining future
violations of, or prohibiting or mandating activities subject to, federal or
state securities laws or finding any violation with respect to such laws.
Item 3. Source and Amount of Funds or Other Consideration.
-------------------------------------------------
Item 3 to the Schedule 13D is hereby amended to add the following
information:
Pursuant to the terms of a Securities Purchase Agreement dated
September 15, 2000 (the "Purchase Agreement") by and between BioSource, on the
one hand, and Genstar Capital Partners, on the other hand, BioSource agreed to
issue and sell, and Genstar Capital Partners agreed to purchase, 300,000 shares
of Common Stock (the "Shares") for a purchase price per Share of $15.00, or an
aggregate purchase price of $4,500,000. Subject to the terms of the Purchase
Agreement, Genstar Capital Partners will assign the right to purchase (i) 3,333
of the Shares to Mr. Weltman, (ii) 30,000 of the Shares to Mr. Conte, (iii)
16,667 of the Shares to Mr. Hoskins and (iv) 16,667 of the Shares to Mr.
Paterson.
Genstar Capital Partners will fund the acquisition of the Shares with
capital contributions from its partners. Messrs. Weltman, Conte, Hoskins and
Paterson will fund the acquisition of the Shares with personal funds.
A copy of the Purchase Agreement is attached hereto as Exhibit 4 and
is incorporated by reference herein.
Item 4. Purpose of the Transaction.
--------------------------
Item 4 to the Schedule 13D is hereby amended to add the following
information:
Pursuant to the terms of a Securities Purchase Agreement dated
September 15, 2000 (the "Purchase Agreement") by and between BioSource, on the
one hand, and Genstar Capital Partners, on the other hand, BioSource agreed to
issue and sell, and Genstar Capital Partners agreed to purchase, 300,000 shares
of Common Stock (the "Shares") for a purchase price per Share of $15.00, or an
aggregate purchase price of $4,500,000. Subject to the terms of the Purchase
Agreement, Genstar Capital Partners will assign the right to purchase (i) 3,333
of the Shares to Mr. Weltman, (ii) 30,000 of the Shares to Mr. Conte, (iii)
16,667 of the Shares to Mr. Hoskins and (iv) 16,667 of the Shares to Mr.
Paterson. A copy of the Purchase Agreement is attached hereto as Exhibit 4 and
is incorporated by reference herein. A copy of the Amendment to the Investor
Rights Agreement, which provides that the Shares shall constitute "Registrable
Securities" under the Investor Rights Agreement, is attached hereto as Exhibit 5
and is incorporated by reference herein.
Pursuant to Section 5.2(ii) of the Certificate of Designations, on
September 21, 2000, the 364,244 shares of the Company's Series B Preferred Stock
("Series B Preferred Stock") held by Genstar Capital Partners and the 7,056
shares of Series B Preferred Stock held by Stargen were automatically converted
into 1,456,976 shares of Common Stock and 28,224 shares of Common Stock,
respectively.
Item 5. Interest in Securities of the Issuer.
------------------------------------
Item 5 to the Schedule 13D is hereby amended to add the following
information:
(a) and (b). As a result of the conversion of the shares of Series B
Preferred Stock described below under Item 5(c), Genstar Capital Partners
beneficially owns 2,967,220 shares of Common Stock, which represents 26.6% of
the Common Stock outstanding (assuming exercise of the Warrants held by Genstar
Capital Partners). As a result of the conversion of the shares of Series B
Preferred Stock described below under Item 5(c), Stargen beneficially owns
57,480 shares of Common Stock, which represents 0.6% of the Common Stock
outstanding (assuming exercise of the Warrants held by Stargen). As a result of
the conversion of the shares of Series B Preferred Stock described below under
Item 5(c), the Reporting Persons beneficially own 3,024,700 shares of Common
Stock, which represents 27.0% of the Common Stock outstanding (assuming exercise
of the Warrants held by Genstar Capital Partners and Stargen). As of the close
of business on September 21, 2000, none of Messrs. Weltman, Conte, Hoskins or
Paterson beneficially owned any Common Stock directly. Following Genstar Capital
Partners' assignment of the right to purchase a portion of the Shares to each of
Messrs. Weltman, Conte, Hoskins and Paterson and assuming the consummation of
the sale of the Shares pursuant to the Purchase Agreement, (i) Mr. Weltman will
acquire 3,333 shares of Common Stock, (ii) Mr. Conte will acquire 30,000 shares
of Common Stock, (iii) Mr. Hoskins will acquire 16,667 shares of Common Stock
and (iv) Mr. Paterson will acquire 16,667 shares of Common Stock.
Genstar Capital Partners has the sole power to dispose or direct the
disposition of the Warrants and shares of Common Stock which it holds directly
or the shares of Common Stock issued upon exercise of such Warrants. Genstar
Capital Partners does not have the power to vote or direct the vote of any of
the shares of Common Stock which it would own upon exercise of such Warrants
prior to the receipt of such shares of Common Stock upon exercise of such
Warrants. Genstar Capital Partners has the power to vote or direct the vote of
the shares of Common Stock which it holds directly.
Genstar Capital is the sole general partner of Genstar Capital
Partners and in such capacity may be deemed to have the power to dispose or
direct the disposition of the Warrants and shares of Common Stock held by
Genstar Capital Partners, and shares of Common Stock which Genstar Capital
Partners would hold upon exercise of such Warrants, and to vote or direct the
vote of such shares of Common Stock.
Stargen has the sole power to dispose or direct the disposition of the
Warrants and shares of Common Stock which it holds directly and the shares of
Common Stock issued upon exercise of such Warrants. Stargen does not have the
power to vote or direct the vote of any of the shares of Common Stock which it
would own upon exercise of such Warrants prior to the receipt of such shares of
Common Stock upon exercise of such Warrants. Stargen has the power to vote or
direct the vote of the shares of Common Stock which it holds directly.
Messrs. Conte, Hoskins and Paterson are the managers and managing
directors of Genstar Capital and are members of Stargen, and Mr. Paterson is the
Administrative Member of Stargen, and in such capacity may be deemed to have the
power to dispose or direct the disposition of the Warrants and shares of Common
Stock held by the Investors, and shares of Common Stock which the Investors
would own upon exercise of such Warrants, and may be deemed to have the power to
vote or direct the vote of such shares of Common Stock. Mr. Weltman is a Vice
President and a member (but not a managing member) of Genstar Capital and a
member (but not a managing member) of Stargen. Mr. Weltman does not have power
to vote or dispose of, or to direct the voting or disposition of, any securities
beneficially owned by Genstar Capital or Stargen. Mr. Weltman disclaims that he
beneficially owns any shares of Common Stock beneficially owned by Genstar
Capital Partners or Stargen, except to the extent of his economic interest
therein.
On and after the Closing Date (as defined in the Securities Purchase
Agreement), each of Messrs. Weltman, Conte, Hoskins and Paterson will have the
sole power to dispose or direct the disposition of, and to vote or direct the
vote of, the shares of Common Stock that each of them will directly hold after
the consummation of the transactions contemplated thereby.
The Reporting Persons and Mr. Weltman may be deemed to be acting as a
group in relation to their respective holdings in BioSource, but do not affirm
the existence of any such group.
Except as set forth in this Item 5(a)-(b), each of the persons named
in this Item 5(a)-(b) disclaims beneficial ownership of any Common Stock owned
beneficially or of record by any other person named in this Item 5(a)-(b).
(c) Pursuant to the terms of a Securities Purchase Agreement dated
September 15, 2000 (the "Purchase Agreement") by and between BioSource, on the
one hand, and Genstar Capital Partners, on the other hand, BioSource agreed to
issue and sell, and Genstar Capital Partners agreed to purchase, 300,000 shares
of Common Stock (the "Shares") for a purchase price per Share of $15.00, or an
aggregate purchase price of $4,500,000. Subject to the terms of the Purchase
Agreement, Genstar Capital Partners will assign the right to purchase (a) 3,333
of the Shares to Mr. Weltman, (b) 30,000 of the Shares to Mr. Conte, (c) 16,667
of the Shares to Mr. Hoskins and (d) 16,667 of the Shares to Mr. Paterson. A
copy of the Purchase Agreement is attached hereto as Exhibit 4 and is
incorporated by reference herein. A copy of the Amendment to the Investor
Rights Agreement, which provides that the Shares shall constitute "Registrable
Securities" under the Investor Rights Agreement, is attached hereto as Exhibit 5
and is incorporated by reference herein.
Pursuant to Section 5.2(ii) of the Certificate of Designations, on
September 21, 2000, the 364,244 shares of the Company's Series B Preferred Stock
("Series B Preferred Stock") held by Genstar Capital Partners and the 7,056
shares of Series B Preferred Stock held by Stargen were automatically converted
into 1,456,976 shares of Common Stock and 28,224 shares of Common Stock,
respectively.
(d) Not applicable.
(e) Not applicable.
Item 6. Contracts, Arrangements, Understandings or Relationships With Respect
---------------------------------------------------------------------
to Securities of the Issuer.
---------------------------
Item 6 to the Schedule 13D is hereby amended to add the following
information:
9
<PAGE>
Pursuant to the terms of a Securities Purchase Agreement dated
September 15, 2000 (the "Purchase Agreement") by and between BioSource, on the
one hand, and Genstar Capital Partners, on the other hand, BioSource agreed to
issue and sell, and Genstar Capital Partners agreed to purchase, 300,000 shares
of Common Stock (the "Shares") for a purchase price per Share of $15.00, or an
aggregate purchase price of $4,500,000. Subject to the terms of the Purchase
Agreement, Genstar Capital Partners will assign the right to purchase (i) 3,333
of the Shares to Mr. Weltman, (ii) 30,000 of the Shares to Mr. Conte, (iii)
16,667 of the Shares to Mr. Hoskins and (iv) 16,667 of the Shares to Mr.
Paterson. A copy of the Purchase Agreement is attached hereto as Exhibit 4 and
is incorporated by reference herein. A copy of the Amendment to the Investor
Rights Agreement, which provides that the Shares shall constitute "Registrable
Securities" under the Investor Rights Agreement, is attached hereto as Exhibit 5
and is incorporated by reference herein.
Item 7. Material to be Filed as Exhibits.
--------------------------------
Exhibit 1 Joint Filing Agreement.
Exhibit 2 Power of Attorney (incorporated by reference to the
Schedule 13D).
Exhibit 3 Power of Attorney.
Exhibit 4 Securities Purchase Agreement between BioSource and Genstar
Capital Partners, dated as of September 15, 2000.
Exhibit 5 Amendment, dated as of September 18, 2000, by and among
BioSource, Genstar Capital Partners, Stargen, Russell D.
Hays and George Uveges, to the Investor Rights Agreement,
dated as of February 15, 2000, by and among BioSource,
Genstar Capital Partners and Stargen.
10
<PAGE>
SIGNATURE
---------
After reasonable inquiry and to the best of each of the undersigned's
knowledge and belief, each of the undersigned certifies that the information set
forth in this statement is true, complete and correct.
Dated: September 22, 2000
GENSTAR CAPITAL LLC
By: /s/ Jean-Pierre L. Conte
-------------------------
Name: Jean-Pierre L. Conte
Its: Managing Member
GENSTAR CAPITAL PARTNERS II, L.P.
By: Genstar Capital LLC, its general partner
By: /s/ Jean-Pierre L. Conte
-------------------------
Name: Jean-Pierre L. Conte
Its: Managing Member
STARGEN II LLC
By: /s/ Jean-Pierre L. Conte
-------------------------
Name: Jean-Pierre L. Conte
Its: Member
/s/ Jean-Pierre L. Conte
--------------------------
Jean-Pierre L. Conte
/s/ Jean-Pierre L. Conte
--------------------------
Jean-Pierre L. Conte
Attorney-in-fact for
Richard F. Hoskins
/s/ Jean-Pierre L. Conte
--------------------------
Jean-Pierre L. Conte
Attorney-in-fact for
Richard D. Paterson
/s/ Jean-Pierre L. Conte
--------------------------
Jean-Pierre L. Conte
Attorney-in-fact for
Robert J. Weltman
11
<PAGE>
EXHIBIT INDEX
-------------
Exhibit 1 Joint Filing Agreement.
Exhibit 2 Power of Attorney (incorporated by reference to
the Schedule 13D).
Exhibit 3 Power of Attorney.
Exhibit 4 Securities Purchase Agreement between BioSource
and Genstar Capital Partners, dated as of September 15,
2000.
Exhibit 5 Amendment, dated as of September 18, 2000, by and among
BioSource, Genstar Capital Partners, Stargen, Russell D.
Hays and George Uveges, to the Investor Rights Agreement,
dated as of February 15, 2000, by and among BioSource,
Genstar Capital Partners and Stargen.
12
